244 Results

People

  1. Giralt
    Giralt
  2. Perales
    Perales
  3. Boelens
    Boelens
  4. O'Reilly
    O'Reilly
  5. Zelenetz
    Zelenetz
  6. Castro-Malaspina
    Castro-Malaspina
  7. Moskowitz
    Moskowitz
  8. Papadopoulos
    Papadopoulos
  9. Yahalom
    Yahalom
  10. Hsu
    Hsu

Groups

  1. Department of Medicine (126)
  2. Center for Hematologic Malignancies (105)
  3. Hematologic Malignancies, Division of (99)
  4. Bone Marrow Transplant (55)
  5. Pediatrics, Department of (49)
  6. GSK Faculty (46)
  7. Survivorship Research (43)
  8. Tow Center for Developmental Oncology (TCDO) (43)
  9. Surgery (32)
  10. Sloan Kettering Institute Faculty (31)
  1. "relapse"
Formats
  1. Journal Article (214)
  2. Review (10)
  3. Book Section (5)
  4. Guidelines (5)
  5. Conference Paper (3)
  6. Research Letter (3)
  7. Meeting Abstract (2)
  8. Correspondence (1)
  9. Editorial (1)
Groups
  1. Department of Medicine (126)
  2. Center for Hematologic Malignancies (105)
  3. Hematologic Malignancies, Division of (99)
  4. Bone Marrow Transplant (55)
  5. Pediatrics, Department of (49)
  6. GSK Faculty (46)

More Groups

People
  1. Sergio Giralt (21)
  2. Miguel-Angel Perales (17)
  3. Andrew Zelenetz (11)
  4. Jaap Jan Boelens (11)
  5. Richard O'Reilly (11)
  6. Craig Moskowitz (10)

More People

Years
  1. 2025 (9)
  2. 2024 (20)
  3. 2023 (11)
  4. 2022 (13)
  5. 2021 (7)
  6. 2020 (8)

More Years

Publications
  1. Blood (22)
  2. Biology of Blood and Marrow Transplantation (18)
  3. Journal of Clinical Oncology (13)
  4. Transplantation and Cellular Therapy (12)
  5. Bone Marrow Transplantation (8)
  6. Blood Advances (7)

More Publications

Publishers
  1. Elsevier Inc. (57)
  2. American Society of Hematology (29)
  3. Elsevier Science, Inc. (16)
  4. Nature Publishing Group (16)
  5. American Society of Clinical Oncology (15)
  6. Wiley Blackwell (11)

More Publishers

Results (244)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: An International Myeloma Foundation immunotherapy database real-world analysis: IMMUNOTHERAPY
    Correspondence

    Mian, H.; Martin, T. G.; Pond, G. R.; Asoori, S.; Popat, R.; Kastritis, E.; Martinez-Lopez, J.; Abdallah, N.; Chhabra, S.; Parrondo, R.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
    Journal Article

    Shah, B. D.; Cassaday, R. D.; Park, J. H.; Houot, R.; Logan, A. C.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; O’Dwyer, K. M.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Clinical use of measurable residual disease in adult ALL: Recommendations from a panel of US experts
    Review

    Short, N. J.; Aldoss, I.; DeAngelo, D. J.; Konopleva, M.; Leonard, J.; Logan, A. C.; Park, J.; Shah, B.; Stock, W.; Jabbour, E.
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Outcomes of older adults and frail patients receiving idecabtagene vicleucel: A CIBMTR study
    Research Letter

    Akhtar, O. S.; Oloyede, T.; Brazauskas, R.; Afrough, A.; Hashmi, H.; Sidana, S.; Ahmed, N.; Bye, M.; Hansen, D.; Ferreri, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • The Association of HLA-E ligand and NKG2 receptor variation with relapse and mortality after haploidentical related donor transplantation
    Journal Article

    Petersdorf, E. W.; McKallor, C.; Malkki, M.; Hsu, K.; He, M.; Spellman, S. R.; Gooley, T.; Stevenson, P.
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: A real-world analysis from 21 US centers
    Journal Article

    Zelikson, V.; Gurumurthi, A.; Sawalha, Y.; Annunzio, K.; Saha, A.; Dong, N.; Qualls, D.; Amoozgar, B.; Kahl, B.; Baird, J.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • A phase II study of acimtamig (AFM13) in patients with CD30-positive, relapsed, or refractory peripheral T-cell lymphomas
    Journal Article

    Kim, W. S.; Shortt, J.; Zinzani, P. L.; Mikhailova, N.; Radeski, D.; Ribrag, V.; Domenech, E. D.; Sawas, A.; Alexis, K.; Emig, M.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis
    Journal Article

    Liu, Y. L.; Mathews, C. A.; Simpkins, F.; Cadoo, K. A.; Provencher, D.; McCormick, C. C.; ElNaggar, A. C.; Altman, A. D.; Gilbert, L.; Black, D.; more...
    Cancer (2025)

    Fulltext@MSK | Save
  • Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
    Journal Article

    Valtis, Y. K.; Devlin, S.; Shouval, R.; Rejeski, K.; Corona, M.; De Abia, A. L.; Rivas-Delgado, A.; Luttwak, E.; Cassanello, G.; Landego, I.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study
    Journal Article

    Zinzani, P. L.; Izutsu, K.; Mehta-Shah, N.; Barta, S. K.; Ishitsuka, K.; Córdoba, R.; Kusumoto, S.; Bachy, E.; Cwynarski, K.; Gritti, G.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save